<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  
                    <script>var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"543865",ustr:"",originlat:"0",clientrtt:"24",ghostip:"104.114.72.134",ipv6:true,pct:"10",clientip:"2603:7000:2a00:89b9:35c1:5791:449a:8f60",requestid:"247e364",region:"35456",protocol:"h2",blver:14,akM:"dsca",akN:"ae",akTT:"O",akTX:"1",akTI:"247e364",ai:"417031",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}</script>
                    </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-dfe9c520699afdbef75fad511280d2f9d3a582cf76458123b4729d29c9687a6e">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?items_per_page_toggle=1&amp;page=9&amp;order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?items_per_page_toggle=1&amp;page=9&amp;order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-02-21T19:55:00Z" timezone="America/New_York" class="datetime">Feb 21, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/us-food-and-drug-administration-approves-kalydecotm-ivacaftor" hreflang="en">U.S. Food and Drug Administration Approves KALYDECO™ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -KALYDECO is the first medicine to treat the underlying cause of CF for people with specific mutations in the CFTR gene- -KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein- -The eight additional mutations are present in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/us-food-and-drug-administration-approves-kalydecotm-ivacaftor" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/d2bc4c18-0a58-42f0-9a8c-eeb70b56bcd6" type="application/pdf" title="VRTX_News_2014_2_21_General.pdf">U.S. Food and Drug Administration Approves KALYDECO&#8482; (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis</a></span><span class="filesize"> 26.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-01-29T21:01:00Z" timezone="America/New_York" class="datetime">Jan 29, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2013-financial" hreflang="en">Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Full-year 2013 total revenues of $1.21 billion , including net product revenues of $371.3 million for KALYDECO in cystic fibrosis and $466.3 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.47 billion on December 31, 2013- -Company expects
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2013-financial" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a457edc0-4e00-4856-bcfe-0ea91419e47d" type="application/pdf" title="VRTX_News_2014_1_29_General.pdf">Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014</a></span><span class="filesize"> 89.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-01-13T00:11:00Z" timezone="America/New_York" class="datetime">Jan 12, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reviews-corporate-strategy-and-outlines-key-2014-business" hreflang="en">Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P. Morgan Healthcare Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -KALYDECO: 2014 revenue growth anticipated from geographic expansion and approval for use in patients with additional CFTR mutations- -Lumacaftor in combination with ivacaftor: results from two Phase 3 studies, TRAFFIC and TRANSPORT, expected mid-year in people with two copies of the F508del
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reviews-corporate-strategy-and-outlines-key-2014-business" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b83154bb-2579-41af-adfb-d5827f039562" type="application/pdf" title="VRTX_News_2014_1_12_General.pdf">Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P. Morgan Healthcare Conference</a></span><span class="filesize"> 35.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-01-09T13:30:00Z" timezone="America/New_York" class="datetime">Jan 9, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-sustained-viral-response-rate-svr4-data-all" hreflang="en">Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first data from the initial cohorts of an open-label Phase 2a study of VX-135, Vertex&#039;s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor, in combination with daclatasvir, Bristol-Myers
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-sustained-viral-response-rate-svr4-data-all" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/4ddadf7b-d0f3-49bd-9cbf-34d693fa0a2f" type="application/pdf" title="VRTX_News_2014_1_9_General.pdf">Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C</a></span><span class="filesize"> 15.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-01-08T21:00:00Z" timezone="America/New_York" class="datetime">Jan 8, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-appointment-jeffrey-chodakewitz-md-chief" hreflang="en">Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz , M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-appointment-jeffrey-chodakewitz-md-chief" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/c720fdef-754a-492c-adce-0f78cde2e8f8" type="application/pdf" title="VRTX_News_2014_1_8_General.pdf">Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development</a></span><span class="filesize"> 13.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-12-19T12:30:00Z" timezone="America/New_York" class="datetime">Dec 19, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-results-phase-3-study-ivacaftor-people-cf-who" hreflang="en">Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Mean absolute treatment difference in lung function across all patients was 2.1 percentage points (p=0.20) and mean relative treatment difference was 5.0% (p=0.06)(n=69); study did not meet its primary endpoint- -Pre-specified analysis of patients 18 years of age and older (n=50) showed
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-results-phase-3-study-ivacaftor-people-cf-who" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7057d5f6-f72e-47ae-87d0-0271c74af856" type="application/pdf" title="VRTX_News_2013_12_19_General.pdf">Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation</a></span><span class="filesize"> 32 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-11-20T08:00:00Z" timezone="America/New_York" class="datetime">Nov 20, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-sells-incivo-r-product-royalty-rights-152-million" hreflang="en">Vertex Sells INCIVO ® Product Royalty Rights for $152 Million</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Vertex to receive $152 million cash payment from Janssen in 2013; will no longer receive royalties on INCIVO sales beginning in 2014- -Company increases 2013 year-end guidance for cash, cash equivalents and marketable securities to in excess of $1.4 billion - CAMBRIDGE, Mass.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-sells-incivo-r-product-royalty-rights-152-million" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/58c72a6d-3507-4ba7-b53a-339a848683bc" type="application/pdf" title="VRTX_News_2013_11_20_General.pdf">Vertex Sells INCIVO &#174; Product Royalty Rights for $152 Million</a></span><span class="filesize"> 16.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-10-29T12:04:00Z" timezone="America/New_York" class="datetime">Oct 29, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2013-financial-results-and-provides" hreflang="en">Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Third quarter 2013 total revenues of $222 million , including net product revenues of $101 million for KALYDECO in cystic fibrosis and $86 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.42 billion on September 30, 2013- -Company reduces
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2013-financial-results-and-provides" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5b717d10-a9cb-40f9-8f07-12330d94d7b4" type="application/pdf" title="VRTX_News_2013_10_29_General.pdf">Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014</a></span><span class="filesize"> 16.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-10-29T12:04:00Z" timezone="America/New_York" class="datetime">Oct 29, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-focuses-investment-future-opportunities-cystic-fibrosis" hreflang="en">Vertex Focuses Investment on Future Opportunities in Cystic Fibrosis and Other Key Research and Development Programs and Reduces Workforce Related to INCIVEK</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Changes result from the continued and rapid decline in the number of people being treated with INCIVEK as new hepatitis C medicines near approval- -370 positions, including 175 in Massachusetts , to be eliminated, primarily related to support of INCIVEK- CAMBRIDGE, Mass.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-focuses-investment-future-opportunities-cystic-fibrosis" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5b717d10-a9cb-40f9-8f07-12330d94d7b4" type="application/pdf" title="VRTX_News_2013_10_29_General.pdf">Vertex Focuses Investment on Future Opportunities in Cystic Fibrosis and Other Key Research and Development Programs and Reduces Workforce Related to INCIVEK</a></span><span class="filesize"> 16.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-10-18T21:36:00Z" timezone="America/New_York" class="datetime">Oct 18, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/oral-selective-jak3-inhibitor-vx-509-showed-statistically" hreflang="en">Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -All doses of VX-509 showed statistically significant ACR20 and ACR50 responses compared to placebo and statistically significant improvement from baseline in DAS28 compared to placebo- -Three highest doses of VX-509: ACR20 of 58% to 68% versus 18% for placebo; statistically significant ACR70
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4041&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Other</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/oral-selective-jak3-inhibitor-vx-509-showed-statistically" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/9f2b395b-adcf-4102-8624-ee9f758a3f2d" type="application/pdf" title="VRTX_News_2013_10_18_General.pdf">Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study</a></span><span class="filesize"> 30.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-10-17T13:00:00Z" timezone="America/New_York" class="datetime">Oct 17, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-recent-progress-and-upcoming-milestones" hreflang="en">Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Enrollment complete for TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in combination with ivacaftor for people with two copies of the F508del mutation (homozygous); data expected in mid-2014- -12-week Phase 2 study of VX-661 in combination with ivacaftor planned for people with two
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-recent-progress-and-upcoming-milestones" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/122419ad-5d66-4f73-9625-f34d245f7a6c" type="application/pdf" title="VRTX_News_2013_10_17_General.pdf">Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis</a></span><span class="filesize"> 35.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-09-30T12:00:00Z" timezone="America/New_York" class="datetime">Sep 30, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-submits-supplemental-new-drug-application-snda-us-food-0" hreflang="en">Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for KALYDECO™ (ivacaftor) Monotherapy for People with Non-G551D Gating Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -sNDA also includes long-term safety and efficacy data for KALYDECO from PERSIST open-label rollover study- -Marketing Authorization Application (MAA) variation in Europe planned for October 2013 - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-submits-supplemental-new-drug-application-snda-us-food-0" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/2d3bfb2a-6244-4d52-a0d1-76c204cf6bb2" type="application/pdf" title="VRTX_News_2013_9_30_General.pdf">Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for KALYDECO&#8482; (ivacaftor) Monotherapy for People with Non-G551D Gating Mutations</a></span><span class="filesize"> 23.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-09-25T20:01:00Z" timezone="America/New_York" class="datetime">Sep 25, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2013-financial-results-october-29" hreflang="en">Vertex to Announce Third Quarter 2013 Financial Results on October 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2013 financial results on Tuesday, October 29, 2013 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2013-financial-results-october-29" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/491039d6-e85c-452c-953a-206955422e6c" type="application/pdf" title="VRTX_News_2013_9_25_Webcasts.pdf">Vertex to Announce Third Quarter 2013 Financial Results on October 29</a></span><span class="filesize"> 10 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-07-29T20:01:00Z" timezone="America/New_York" class="datetime">Jul 29, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/results-phase-3-study-ivacaftor-monotherapy-showed-statistically" hreflang="en">Results from Phase 3 Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People with non-G551D Gating Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Mean absolute treatment difference in lung function (percent predicted FEV 1 ) between treatment with ivacaftor and placebo was 10.7% (p &amp;lt; 0.0001); mean relative treatment difference between treatment with ivacaftor and placebo was 14.2% (p &amp;lt; 0.0001)- -Statistically significant improvements
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/results-phase-3-study-ivacaftor-monotherapy-showed-statistically" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e45980ec-47ba-41fb-bc2d-9e2f1f0f9053" type="application/pdf" title="VRTX_News_2013_7_29_General.pdf">Results from Phase 3 Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People with non-G551D Gating Mutations</a></span><span class="filesize"> 87.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-07-29T20:00:00Z" timezone="America/New_York" class="datetime">Jul 29, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2013-financial-results-and-reviews" hreflang="en">Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Second quarter 2013 total revenues of $311 million , including net product revenues of $99 million for KALYDECO in cystic fibrosis and $156 million for INCIVEK in hepatitis C; cash position of approximately $1.43 billion on June 30, 2013 - -Data from Phase 3 study of ivacaftor monotherapy support
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2013-financial-results-and-reviews" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e45980ec-47ba-41fb-bc2d-9e2f1f0f9053" type="application/pdf" title="VRTX_News_2013_7_29_General.pdf">Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs</a></span><span class="filesize"> 87.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-07-25T20:04:00Z" timezone="America/New_York" class="datetime">Jul 25, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-provides-update-ongoing-all-oral-studies-vx-135-hepatitis" hreflang="en">Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -U.S. Study: FDA places partial clinical hold on ongoing Phase 2 U.S. study of VX-135, preventing evaluation of 200 mg dose following observation of elevated liver enzymes in patients receiving 400 mg of VX-135 in combination with ribavirin in Phase 2 study in Europe ; evaluation of 100 mg dose
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-provides-update-ongoing-all-oral-studies-vx-135-hepatitis" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/6b41a961-04db-42b6-b73e-04b171eb10ac" type="application/pdf" title="VRTX_News_2013_7_25_General.pdf">Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C</a></span><span class="filesize"> 19.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-07-09T21:20:00Z" timezone="America/New_York" class="datetime">Jul 9, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-australian-approval-kalydecotm-ivacaftor-first" hreflang="en">Vertex Receives Australian Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -- Approximately 250 people in Australia have the G551D mutation in the CFTR gene -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods Administration (TGA) of Australia has approved KALYDECO™ (ivacaftor) for people
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-australian-approval-kalydecotm-ivacaftor-first" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/83a14869-2349-42fe-b88b-a007094885a2" type="application/pdf" title="VRTX_News_2013_7_9_General.pdf">Vertex Receives Australian Approval for KALYDECO&#8482; (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)</a></span><span class="filesize"> 23 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-06-18T12:30:00Z" timezone="America/New_York" class="datetime">Jun 18, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-completes-redemption-convertible-senior-subordinated" hreflang="en">Vertex Completes Redemption of Convertible Senior Subordinated Notes</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-completes-redemption-convertible-senior-subordinated" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/3602345a-6962-47e5-8c34-ae760e0f06cd" type="application/pdf" title="VRTX_News_2013_6_18_General.pdf">Vertex Completes Redemption of Convertible Senior Subordinated Notes</a></span><span class="filesize"> 8.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-05-17T12:30:00Z" timezone="America/New_York" class="datetime">May 17, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-calls-redemption-400-million-convertible-senior" hreflang="en">Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -2015 Notes convertible at a conversion price of approximately $48.83 per share- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it has called for redemption of its outstanding $400.0 million in aggregate principal amount of 3.35% Convertible
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-calls-redemption-400-million-convertible-senior" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a31e9139-fdd3-4775-ba0a-b4b33dfa2412" type="application/pdf" title="VRTX_News_2013_5_17_General.pdf">Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015</a></span><span class="filesize"> 12.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-04-30T20:03:00Z" timezone="America/New_York" class="datetime">Apr 30, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2013-financial-results-and-reviews" hreflang="en">Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -First quarter 2013 total revenues of $328 million , including net product revenues of $206 million for INCIVEK in hepatitis C and $62 million for KALYDECO in cystic fibrosis- -Cystic fibrosis: Enrollment ongoing in Phase 3 program for VX-809 in combination with ivacaftor for people with two copies
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2013-financial-results-and-reviews" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/8baaedbf-9445-42df-bcad-c8d887e43972" type="application/pdf" title="VRTX_News_2013_4_30_General.pdf">Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C</a></span><span class="filesize"> 69.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-04-24T12:30:00Z" timezone="America/New_York" class="datetime">Apr 24, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-new-data-showed-high-viral-cure-rates-total-12" hreflang="en">Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Interim analysis of the Phase 3b CONCISE study showed SVR12 rates of 87 percent with 12 total weeks of treatment and 97 percent with 24 total weeks of treatment among people who achieved RVR and completed 12 weeks of treatment - AMSTERDAM --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-new-data-showed-high-viral-cure-rates-total-12" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/6ee9b727-d355-41ca-86bc-930e3ce68408" type="application/pdf" title="VRTX_News_2013_4_24_General.pdf">Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype</a></span><span class="filesize"> 29.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-04-23T12:30:00Z" timezone="America/New_York" class="datetime">Apr 23, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/als-2200-vx-135-viral-kinetic-study-shows-significant-reduction" hreflang="en">ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - After seven days of once-daily dosing with 200 mg of ALS-2200, genotype 1 patients with cirrhosis had a median 4.08 log 10 reduction in HCV RNA; among people with genotypes 3 or 4, there was a median 4.65 log 10 reduction in HCV RNA - - Data are consistent with previously reported ALS-2200
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/als-2200-vx-135-viral-kinetic-study-shows-significant-reduction" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/3e370a3b-6a39-46d3-8929-27bb15dd7c13" type="application/pdf" title="VRTX_News_2013_4_23_General.pdf">ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection</a></span><span class="filesize"> 30.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-04-18T20:00:00Z" timezone="America/New_York" class="datetime">Apr 18, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/treatment-vx-661-and-ivacaftor-phase-2-study-resulted" hreflang="en">Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Treatment with combination of VX-661 and ivacaftor for 28 days in two highest dose groups resulted in mean relative increases in lung function (percent predicted FEV 1 ) of 9.0% (p=0.01) and 7.5% (p=0.02) versus placebo - -VX-661 was generally well-tolerated alone and in combination with
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/treatment-vx-661-and-ivacaftor-phase-2-study-resulted" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/f21bf6a9-471c-4a16-8ece-b99f510477ec" type="application/pdf" title="VRTX_News_2013_4_18_General.pdf">Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 30.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-04-05T12:00:00Z" timezone="America/New_York" class="datetime">Apr 5, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-enters-agreement-bristol-myers-squibb-phase-2-all-oral" hreflang="en">Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Two Phase 2 studies to evaluate once-daily combination of Vertex&#039;s investigational nucleotide analogue VX-135 and BMS&#039; investigational NS5A replication complex inhibitor daclatasvir- -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013- -Study in people with
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-enters-agreement-bristol-myers-squibb-phase-2-all-oral" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/f034a7b2-e173-4aa0-87b9-4ef90bb86c44" type="application/pdf" title="VRTX_News_2013_4_5_General.pdf">Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C</a></span><span class="filesize"> 25.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-03-04T13:30:00Z" timezone="America/New_York" class="datetime">Mar 4, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vx-787-showed-significant-antiviral-activity-and-reduced" hreflang="en">VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Treatment with highest dosing regimen of VX-787 reduced viral shedding by 94 percent versus placebo; Duration of flu symptoms were reduced by nearly half - - VX-787 is an investigational new class of medicine designed to directly inhibit replication of the influenza virus - CAMBRIDGE, Mass.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4041&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Other</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vx-787-showed-significant-antiviral-activity-and-reduced" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/c3400367-c7d2-4c7a-8e69-b7ccee99b710" type="application/pdf" title="VRTX_News_2013_3_4_General.pdf">VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study</a></span><span class="filesize"> 26.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-02-26T21:22:00Z" timezone="America/New_York" class="datetime">Feb 26, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-initiation-pivotal-phase-3-program-vx-809" hreflang="en">Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Global studies to evaluate two different doses of VX-809 in combination with ivacaftor- - 24-week safety and efficacy data and submission of New Drug Application expected in 2014- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-initiation-pivotal-phase-3-program-vx-809" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/55dd6ee8-f238-476b-b080-6fab0a23b3ae" type="application/pdf" title="VRTX_News_2013_2_26_General.pdf">Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 32.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-02-01T17:38:00Z" timezone="America/New_York" class="datetime">Feb 1, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/republic-ireland-approves-funding-kalydecotm-ivacaftor-first" hreflang="en">Republic of Ireland Approves Funding for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Health Service Executive (HSE) in the Republic of Ireland will fund KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/republic-ireland-approves-funding-kalydecotm-ivacaftor-first" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/d0617b76-0f18-4256-baae-1d3e53d1202b" type="application/pdf" title="VRTX_News_2013_2_1_General.pdf">Republic of Ireland Approves Funding for KALYDECO&#8482; (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)</a></span><span class="filesize"> 19.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-01-29T21:01:00Z" timezone="America/New_York" class="datetime">Jan 29, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2012-financial" hreflang="en">Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -Full-year 2012 revenues of $1.53 billion , including net product revenues of $1.16 billion for INCIVEK in hepatitis C and $171.6 million for KALYDECO in cystic fibrosis- -Company ends 2012
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2012-financial" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/83c0f198-c2b3-4b08-8807-957ba9563e7a" type="application/pdf" title="VRTX_News_2013_1_29_General.pdf">Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs</a></span><span class="filesize"> 80.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2013-01-06T22:00:00Z" timezone="America/New_York" class="datetime">Jan 6, 2013</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-outlines-corporate-strategy-and-defines-key-2013-business" hreflang="en">Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -First two Breakthrough Therapy Designations from U.S. FDA granted to ivacaftor monotherapy and to the combination regimen of VX-809 and ivacaftor for the treatment of cystic fibrosis- SAN
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-outlines-corporate-strategy-and-defines-key-2013-business" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e8522642-e5be-4a4e-9315-0a6bfd5ce23c" type="application/pdf" title="VRTX_News_2013_1_6_General.pdf">Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities</a></span><span class="filesize"> 37.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-12-19T14:45:00Z" timezone="America/New_York" class="datetime">Dec 19, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/nhs-england-funds-kalydecotm-ivacaftor-first-medicine-treat" hreflang="en">NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a decision has been made by the National Health Service (NHS) in England to fund KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/nhs-england-funds-kalydecotm-ivacaftor-first-medicine-treat" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/69a04d67-3848-478a-a414-69cc391a32a3" type="application/pdf" title="VRTX_News_2012_12_19_General.pdf">NHS in England Funds KALYDECO&#8482; (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)</a></span><span class="filesize"> 20.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-12-19T13:31:00Z" timezone="America/New_York" class="datetime">Dec 19, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-update-us-prescribing-information-incivekr" hreflang="en">Vertex Announces Update to U.S. Prescribing Information for INCIVEK® (telaprevir)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Revised label includes Boxed Warning detailing risk of serious skin reactions observed in the post-marketing setting that require treatment discontinuation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the INCIVEK ® (telaprevir)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-update-us-prescribing-information-incivekr" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/69a04d67-3848-478a-a414-69cc391a32a3" type="application/pdf" title="VRTX_News_2012_12_19_General.pdf">Vertex Announces Update to U.S. Prescribing Information for INCIVEK&#174; (telaprevir)</a></span><span class="filesize"> 20.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-12-03T13:30:00Z" timezone="America/New_York" class="datetime">Dec 3, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/health-canada-approves-kalydecotm-ivacaftor-first-medicine-treat" hreflang="en">Health Canada Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -- Approximately 100 people in Canada have the G551D mutation in the CFTR gene -- -- First medicine resulting from 1989 co-discovery of CF gene by researchers in Canada and the U.S. -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/health-canada-approves-kalydecotm-ivacaftor-first-medicine-treat" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/364e5c76-be64-4a64-8fce-4c4717aea44c" type="application/pdf" title="VRTX_News_2012_12_3_General.pdf">Health Canada Approves KALYDECO&#8482; (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)</a></span><span class="filesize"> 25.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-11-15T05:00:00Z" timezone="America/New_York" class="datetime">Nov 15, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/incivektm-telaprevir-now-funded-alberta-and-new-brunswick-people" hreflang="en">INCIVEK™ (telaprevir) Now Funded in Alberta and New Brunswick for People with Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Majority of provinces now fund INCIVEK - 
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/incivektm-telaprevir-now-funded-alberta-and-new-brunswick-people" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a75e492a-a69c-42da-a411-1ad0f7ebe327" type="application/pdf" title="VRTX_News_2012_11_15_General.pdf">INCIVEK<sup>&amp;#8482</sup> (telaprevir) Now Funded in Alberta and New Brunswick for People with Hepatitis C</a></span><span class="filesize"> 28.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-11-10T14:00:00Z" timezone="America/New_York" class="datetime">Nov 10, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-presents-new-phase-3-data-showed-people-hepatitis-c" hreflang="en">Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - New Phase 2 data showed approximately 3 of 4 people co-infected with hepatitis C virus (HCV) and HIV achieved HCV viral cure (SVR24) with telaprevir combination treatment - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from a Phase 3
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-presents-new-phase-3-data-showed-people-hepatitis-c" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e7ca0b2c-6ee1-459b-bb19-04f6ef1c8ccc" type="application/pdf" title="VRTX_News_2012_11_10_General.pdf">Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily</a></span><span class="filesize"> 93.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-11-10T14:00:00Z" timezone="America/New_York" class="datetime">Nov 10, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/data-viral-kinetic-study-showed-rapid-reduction-hcv-rna-als-2200" hreflang="en">Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex&#039;s Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - 4.54 log 10 median reduction in HCV RNA after 7 days of dosing; ALS-2200 was well-tolerated with no serious adverse events and no discontinuations due to adverse events - - Vertex moving forward with multiple Phase 2 trials in early 2013 exploring all-oral combinations, including VX-135 with
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/data-viral-kinetic-study-showed-rapid-reduction-hcv-rna-als-2200" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e7ca0b2c-6ee1-459b-bb19-04f6ef1c8ccc" type="application/pdf" title="VRTX_News_2012_11_10_General.pdf">Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C</a></span><span class="filesize"> 93.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-11-01T20:00:00Z" timezone="America/New_York" class="datetime">Nov 1, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2012-financial-results-and-recent" hreflang="en">Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Third quarter 2012 total revenues of $336 million , including third quarter 2012 net product revenues of approximately $254 million for INCIVEK in hepatitis C and $49 million for KALYDECO in cystic fibrosis- -Cystic Fibrosis: Three ongoing Phase 3 label expansion studies for ivacaftor monotherapy;
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2012-financial-results-and-recent" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/0e21d179-b8df-46bb-889c-1549b3304f54" type="application/pdf" title="VRTX_News_2012_11_1_General.pdf">Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs</a></span><span class="filesize"> 69.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-11-01T11:30:00Z" timezone="America/New_York" class="datetime">Nov 1, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-enters-agreement-glaxosmithkline-phase-2-all-oral-study" hreflang="en">Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Companies to evaluate two-drug combination of Vertex&#039;s investigational nucleotide analogue VX-135 and GSK&#039;s investigational NS5A inhibitor GSK2336805- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen-
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-enters-agreement-glaxosmithkline-phase-2-all-oral-study" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/d9ef15e4-2fe6-40dd-9948-445ea5e1564e" type="application/pdf" title="VRTX_News_2012_11_1_Webcasts.pdf">Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C</a></span><span class="filesize"> 28 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-11-01T11:30:00Z" timezone="America/New_York" class="datetime">Nov 1, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-collaboration-janssen-initiate-phase-2-all-oral" hreflang="en">Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Companies to evaluate two-drug combination of Vertex&#039;s investigational nucleotide analogue VX-135 and Janssen&#039;s investigational protease inhibitor simeprevir (TMC435)- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-collaboration-janssen-initiate-phase-2-all-oral" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/d9ef15e4-2fe6-40dd-9948-445ea5e1564e" type="application/pdf" title="VRTX_News_2012_11_1_Webcasts.pdf">Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C</a></span><span class="filesize"> 28 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-10-16T20:00:00Z" timezone="America/New_York" class="datetime">Oct 16, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-date-its-third-quarter-2012-financial-results" hreflang="en">Vertex Announces the Date of its Third Quarter 2012 Financial Results Conference Call and Webcast</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2012 financial results on Monday, October 29, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-date-its-third-quarter-2012-financial-results" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a44a9bd0-7abd-419d-a0fc-33a4de784c0d" type="application/pdf" title="VRTX_News_2012_10_16_Webcasts.pdf">Vertex Announces the Date of its Third Quarter 2012 Financial Results Conference Call and Webcast</a></span><span class="filesize"> 8.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-10-11T12:30:00Z" timezone="America/New_York" class="datetime">Oct 11, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/data-phase-2-combination-study-vx-809-and-ivacaftor-people" hreflang="en">Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -- Additional KALYDECO™ (ivacaftor) and CF pipeline presentations highlight Vertex&#039;s commitment to advancing CF treatment by targeting the underlying cause of the disease -- ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from a Phase 2
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/data-phase-2-combination-study-vx-809-and-ivacaftor-people" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/599a83de-1319-46d1-b8ea-17d14e2ae42b" type="application/pdf" title="VRTX_News_2012_10_11_Webcasts.pdf">Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference</a></span><span class="filesize"> 28.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-10-01T14:46:00Z" timezone="America/New_York" class="datetime">Oct 1, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-presentation-new-data-hepatitis-c-development" hreflang="en">Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeting</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its hepatitis C research and development program will be presented at The Liver Meeting ® , the 63rd Annual Meeting of the American Association for the Study of Liver
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-presentation-new-data-hepatitis-c-development" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/63115fba-f635-40be-89cf-05f68b9cfe1d" type="application/pdf" title="VRTX_News_2012_10_1_Webcasts.pdf">Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeting</a></span><span class="filesize"> 29.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-09-25T18:55:00Z" timezone="America/New_York" class="datetime">Sep 25, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-presentation-data-north-american-cystic" hreflang="en">Vertex Announces Presentation of Data at North American Cystic Fibrosis Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 10 abstracts from its cystic fibrosis (CF) research and development program will be presented at the 26th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Fla.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-presentation-data-north-american-cystic" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/08006fa8-6de4-4d66-bba0-7fdd83a2abf4" type="application/pdf" title="VRTX_News_2012_9_25_Webcasts.pdf">Vertex Announces Presentation of Data at North American Cystic Fibrosis Conference</a></span><span class="filesize"> 19.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-09-25T12:30:00Z" timezone="America/New_York" class="datetime">Sep 25, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-new-data-als-2200-people-hepatitis-c-supporting" hreflang="en">Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - ALS-2158: Well-tolerated in a seven-day viral kinetic study; development discontinued due to lack of efficacy - - ALS-2200: Data from additional cohort of seven-day viral kinetic study with ALS-2200 (200 mg, QD) in combination with ribavirin show median 4.18 log 10 reduction in HCV RNA with 5 of
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-new-data-als-2200-people-hepatitis-c-supporting" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/08006fa8-6de4-4d66-bba0-7fdd83a2abf4" type="application/pdf" title="VRTX_News_2012_9_25_Webcasts.pdf">Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158</a></span><span class="filesize"> 19.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-09-18T12:30:00Z" timezone="America/New_York" class="datetime">Sep 18, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/yuchun-lee-appointed-vertex-board-directors" hreflang="en">Yuchun Lee Appointed to the Vertex Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Yuchun Lee joined its board of directors as an independent director. Mr. Lee was appointed to the class of directors whose term expires in 2013.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/yuchun-lee-appointed-vertex-board-directors" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/23da2d98-4d29-44f4-8bc9-ed2e3495cf42" type="application/pdf" title="VRTX_News_2012_9_18_Webcasts.pdf">Yuchun Lee Appointed to the Vertex Board of Directors</a></span><span class="filesize"> 11.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-09-04T12:30:00Z" timezone="America/New_York" class="datetime">Sep 4, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-appointment-stuart-arbuckle-chief-commercial" hreflang="en">Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-appointment-stuart-arbuckle-chief-commercial" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5e1c0508-4b7d-4bff-b45e-2c57f4f72143" type="application/pdf" title="VRTX_News_2012_9_4_Webcasts.pdf">Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer</a></span><span class="filesize"> 18.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-07-30T20:03:00Z" timezone="America/New_York" class="datetime">Jul 30, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2012-financial-results-and" hreflang="en">Vertex Reports Second Quarter 2012 Financial Results and Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Second quarter 2012 total revenues of $418 million , including second quarter 2012 net product revenues of approximately $328 million for INCIVEK in hepatitis C and $46 million for KALYDECO in cystic fibrosis; company revises financial guidance for full-year 2012 INCIVEK net revenues- -Cystic
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2012-financial-results-and" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b6fb8243-6126-468a-a811-f6128a16d8fc" type="application/pdf" title="VRTX_News_2012_7_30_Webcasts.pdf">Vertex Reports Second Quarter 2012 Financial Results and Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis</a></span><span class="filesize"> 36.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-07-30T20:00:00Z" timezone="America/New_York" class="datetime">Jul 30, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-results-viral-kinetic-study-nucleotide" hreflang="en">Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - 4.54 log 10 median reduction in HCV RNA observed in people with genotype 1 hepatitis C treated with a once-daily 200 mg dose of ALS-2200 for seven days; treatment was well-tolerated- - Phase 2 studies of 12-week all-oral regimens planned for this year - CAMBRIDGE, Mass.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4036&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>HCV</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-results-viral-kinetic-study-nucleotide" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b6fb8243-6126-468a-a811-f6128a16d8fc" type="application/pdf" title="VRTX_News_2012_7_30_Webcasts.pdf">Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C</a></span><span class="filesize"> 36.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-07-27T08:00:00Z" timezone="America/New_York" class="datetime">Jul 27, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-approval-kalydecotm-ivacaftor-first" hreflang="en">Vertex Receives European Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - European Commission approval comes two months after positive CHMP opinion - GENEVA --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has approved KALYDECO TM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-approval-kalydecotm-ivacaftor-first" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/ca7cfb55-3423-4c55-95d8-e0e5662a27c8" type="application/pdf" title="VRTX_News_2012_7_27_Webcasts.pdf">Vertex Receives European Approval for KALYDECO&#8482; (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)</a></span><span class="filesize"> 84.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-06-28T11:15:00Z" timezone="America/New_York" class="datetime">Jun 28, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/final-data-phase-2-combination-study-vx-809-and-kalydecotm" hreflang="en">Final Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Mean absolute improvement in lung function of 6.1 percentage points within group (p &amp;lt; 0.001) and 8.6 percentage points compared to placebo (p &amp;lt; 0.001) in homozygous patients receiving combination treatment (Day 28 to 56) with highest study dose of VX-809 (600mg) - - Adverse events were
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/final-data-phase-2-combination-study-vx-809-and-kalydecotm" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/1fd06b84-d749-43cb-b742-aa2ebf1a282c" type="application/pdf" title="VRTX_News_2012_6_28_Webcasts.pdf">Final Data from Phase 2 Combination Study of VX-809 and KALYDECO&#8482; (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 90.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2012-06-18T13:30:00Z" timezone="America/New_York" class="datetime">Jun 18, 2012</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-collaboration-boston-public-schools-enhance" hreflang="en">Vertex Announces Collaboration with the Boston Public Schools to Enhance Science Education</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Vertex commits more than $1 million to support education for BPS students and to prepare teachers for new science education standards- -Company dedicates 3,000 square foot learning laboratory at new Fan Pier headquarters to local community- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-collaboration-boston-public-schools-enhance" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/4ea0391b-0347-4778-b8a7-ecb0dfed2985" type="application/pdf" title="VRTX_News_2012_6_18_General.pdf">Vertex Announces Collaboration with the Boston Public Schools to Enhance Science Education</a></span><span class="filesize"> 15.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?items_per_page_toggle=1&amp;page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">First</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?items_per_page_toggle=1&amp;page=8" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">Previous</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=8" title="Go to page 9">
            <span class="visually-hidden">
              Page
            </span>9</a>
        </li>
              <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=9" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>10</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=10" title="Go to page 11">
            <span class="visually-hidden">
              Page
            </span>11</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=11" title="Go to page 12">
            <span class="visually-hidden">
              Page
            </span>12</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=10" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 451 - 500 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"items_per_page_toggle":"1","page":"9"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
